Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study
Abstract
Dapagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, provides glycemic control and has proven cardiovascular and renal benefits in large trials, but its real-world use in Sudan has not been described. This study aimed to describe clinical characteristics, safety, adherence, and outcomes among Sudanese patients prescribed dapagliflozin in routine care. A multicenter retrospective cohort study (April–July 2022) was conducted at three cardiac hospitals in Khartoum, Sudan. Adults ( n = 238) prescribed dapagliflozin for heart failure (HF) were enrolled. Data were obtained from medical records and structured patient interviews, capturing sociodemographic data, adverse events, adherence, hospitalizations, and deaths. Mean age was 60.7 ± 12 years; 55% were male. 96.3% of patients received dapagliflozin at a starting dose of 10 mg once daily. High adherence was reported in 86.1%. Common adverse events were polyuria (65.1%) and urinary tract infection (32.8%). Following dapagliflozin therapy, mean LVEF increased from baseline to follow-up by 5.98 ± 7.39% points among 213 patients with paired LVEF data (paired p < 0.001), whereas HbA1c showed a reduction of 0.91 ± 1.78% points among 158 patients with paired HbA1c data (paired p < 0.001). Cardiovascular death was observed in 4.6% of patients, and HF hospitalization occurred in 7.6%. In this first Sudanese real-world cohort, dapagliflozin was associated with good adherence, observed improvement in LVEF, and an acceptable safety profile, supporting its role in cardiac care in low-resource settings.
Related
- Observed Clinical and Operational Factors Are Associated with Biomarker Test Utilization in Respiratory Virus RT-PCR Testing: A Real-World Analysis of Inflammatory, Cardiac, and Thrombotic Biomarkers.
- Associations of Cancer Rehabilitation During Hospitalization for Cancer Treatment With Survival and Post–Discharge Healthcare Utilization: A Multicenter Retrospective Cohort Study
- Clinical utility of CT-based deep learning for differentiating pulmonary aspergillosis from bacterial pneumonia: a multicenter retrospective study
- Irreparable Posterosuperior Rotator Cuff Tears Treated With InSpace Balloon With or Without Arthroscopic Subscapularis Repair: Short‐Term Clinical Outcomes in a Multicenter Retrospective Study
- Nutritional status, clinical burden, and healthcare utilization among pediatric outpatients with congenital heart disease: A retrospective cross-sectional study from Indonesia
BibTeX
@article{nasreldeen2026realworld,
title = {{Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study}},
author = {Manasik Nasreldeen and Toga K. Mohamed and Anas Babiker and Bashir A. Yousef and Emmanuel Edwar Siddig and Kannan O. Ahmed},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73258-4},
url = {https://www.nature.com/articles/s41598-026-73258-4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study
AU - Manasik Nasreldeen
AU - Toga K. Mohamed
AU - Anas Babiker
AU - Bashir A. Yousef
AU - Emmanuel Edwar Siddig
AU - Kannan O. Ahmed
PY - 2026
DA - 2026/10/04
JO - Scientific Reports
DO - 10.1038/s41598-026-73258-4
UR - https://www.nature.com/articles/s41598-026-73258-4
AB - Dapagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, provides glycemic control and has proven cardiovascular and renal benefits in large trials, but its real-world use in Sudan has not been described. This study aimed to describe clinical characteristics, safety, adherence, and outcomes among Sudanese patients prescribed dapagliflozin in routine care. A multicenter retrospective cohort study (April–July 2022) was conducted at three cardiac hospitals in Khartoum, Sudan. Adults ( n = 238) prescribed dapagliflozin for heart failure (HF) were enrolled. Data were obtained from medical records and structured patient interviews, capturing sociodemographic data, adverse events, adherence, hospitalizations, and deaths. Mean age was 60.7 ± 12 years; 55% were male. 96.3% of patients received dapagliflozin at a starting dose of 10 mg once daily. High adherence was reported in 86.1%. Common adverse events were polyuria (65.1%) and urinary tract infection (32.8%). Following dapagliflozin therapy, mean LVEF increased from baseline to follow-up by 5.98 ± 7.39% points among 213 patients with paired LVEF data (paired p < 0.001), whereas HbA1c showed a reduction of 0.91 ± 1.78% points among 158 patients with paired HbA1c data (paired p < 0.001). Cardiovascular death was observed in 4.6% of patients, and HF hospitalization occurred in 7.6%. In this first Sudanese real-world cohort, dapagliflozin was associated with good adherence, observed improvement in LVEF, and an acceptable safety profile, supporting its role in cardiac care in low-resource settings.
SN - 2045-2322
ER -